The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Ghasoub R, Benkhadra M, Kassem N, Alshurafa A, Elsabah H

Carfilzomib-induced life-threatening lung injury in refractory multiple myeloma.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023 Jul 24;;10781552231190039 — 2023 Jul 24 — 10781552231190039

Marschall A, Merino JCF, Gravalos TL

Fatal pulmonary toxicity following Carfilzomib administration.

Acute medicine 2021;20;286-289 — 2021 — 286-289

Wang M, Cheng J

Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.

Oncology (Williston Park, N.Y.) 2013 Dec;27 Suppl 3;24-30 — 2013 Dec — 24-30